OPTIMISE-CKD Study_Dapagliflozin Effectiveness in CKD

This real-world study is evaluating how well dapagliflozin — a medication originally developed for diabetes but now approved for chronic kidney disease — works in actual patients with chronic kidney disease (CKD) in routine clinical practice. The study uses health records to track kidney function and disease outcomes over time. **You may be eligible if:** - You are 18 years of age or older - You have chronic kidney disease, defined by having a consistently reduced kidney filtration rate (eGFR ≤60 mL/min on at least two readings at least 90 days apart) and/or elevated protein in your urine - You have been continuously enrolled in the healthcare database for at least 12 months before and after the start of dapagliflozin treatment **You may NOT be eligible if:** - You have Type 1 diabetes - You have been diagnosed with gestational diabetes Talk to your doctor to see if this trial is right for you.